0
     

Report Added
Report already added
Consumer Health in Belgium

Consumer Health in Belgium

At first sight, there was a recovery in consumer health in Belgium in 2022 after the first promising steps at the end of 2021 announced a post-COVID-19 situation. However, while current value growth is even higher in 2022 than in 2021, this is mainly due to a natural catch-up effect after 2020 and the first half of 2021 and skyrocketing inflation. Indeed, while volumes are not calculable over consumer health as a whole, gains are likely to be very modest, depending on the evolution of inflation...

Euromonitor International's Consumer Health in Belgium report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management and Wellbeing.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Consumer Health market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Consumer Health in Belgium

List Of Contents And Tables

CONSUMER HEALTH IN BELGIUM
EXECUTIVE SUMMARY
Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 1 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 2 Life Expectancy at Birth 2017-2022
MARKET DATA
Table 3 Sales of Consumer Health by Category: Value 2017-2022
Table 4 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 5 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 6 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 7 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
Table 8 Distribution of Consumer Health by Format: % Value 2017-2022
Table 9 Distribution of Consumer Health by Format and Category: % Value 2022
Table 10 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources
ANALGESICS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
The return of “normal” pathologies comes sooner than anticipated
Topical analgesics/anaesthetic back in business too
Dafalgan and generics benefit from the ongoing breakthrough of acetaminophen
PROSPECTS AND OPPORTUNITIES
Normalisation and thus maturity expected over 2023-2027
Possible risks of shortage, mainly in generics
Other disparate effects
CATEGORY DATA
Table 12 Sales of Analgesics by Category: Value 2017-2022
Table 13 Sales of Analgesics by Category: % Value Growth 2017-2022
Table 14 NBO Company Shares of Analgesics: % Value 2018-2022
Table 15 LBN Brand Shares of Analgesics: % Value 2019-2022
Table 16 Forecast Sales of Analgesics by Category: Value 2022-2027
Table 17 Forecast Sales of Analgesics by Category: % Value Growth 2022-2027
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
Stars aligned for another good performance following a year of catch-up
Premature seasonal allergies: the second stage of the cough, cold and allergy (hay fever) remedies rocket in 2022
Innovation also contributes to the better fate of top players
PROSPECTS AND OPPORTUNITIES
Climatic factors to play important role
Probable saturation in decongestants and competition from more natural remedies
Possible comeback of innovation vs unfavourable context for Rx-to-OTC switches
CATEGORY DATA
Table 18 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2017-2022
Table 19 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2017-2022
Table 20 NBO Company Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2018-2022
Table 21 LBN Brand Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2019-2022
Table 22 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2022-2027
Table 23 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2022-2027
DIGESTIVE REMEDIES IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
‘Gastro’ are back in 2022
Belgians also welcome good old motion sickness
Jansen-Cilag vs Norgine
PROSPECTS AND OPPORTUNITIES
Back to mature development after the catch-up years of 2021 and 2022
Main challenges involve the negative context about Rx-OTC switches and more natural food
Lack of recognition for IBS treatments and the “new generation” indigestion and heartburn remedies
CATEGORY DATA
Table 24 Sales of Digestive Remedies by Category: Value 2017-2022
Table 25 Sales of Digestive Remedies by Category: % Value Growth 2017-2022
Table 26 NBO Company Shares of Digestive Remedies: % Value 2018-2022
Table 27 LBN Brand Shares of Digestive Remedies: % Value 2019-2022
Table 28 Forecast Sales of Digestive Remedies by Category: Value 2022-2027
Table 29 Forecast Sales of Digestive Remedies by Category: % Value Growth 2022-2027
DERMATOLOGICALS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
Late recovery for dermatologicals in 2022 thanks to price increase and catch-up effect in many categories
A little help from a stronger foothold in pharmacies too
Historical leader, Janssen-Cilag NV, benefits from the recovery of dermatologicals
PROSPECTS AND OPPORTUNITIES
Better situation for multiple retail sales but ongoing threats from Rx and beauty and personal care
Can demand for natural products persist in a context of rising inflation?
Despite new COVID-19 waves, the ongoing return to lifestyle activities will help
CATEGORY DATA
Table 30 Sales of Dermatologicals by Category: Value 2017-2022
Table 31 Sales of Dermatologicals by Category: % Value Growth 2017-2022
Table 32 NBO Company Shares of Dermatologicals: % Value 2018-2022
Table 33 LBN Brand Shares of Dermatologicals: % Value 2019-2022
Table 34 LBN Brand Shares of Hair Loss Treatments: % Value 2019-2022
Table 35 Forecast Sales of Dermatologicals by Category: Value 2022-2027
Table 36 Forecast Sales of Dermatologicals by Category: % Value Growth 2022-2027
NRT SMOKING CESSATION AIDS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
New robust growth thanks to taxes on tobacco and prices increase
Tobacco consumption took off during the pandemic in contrast to initial assumptions
Nicorette maintains its position, giving Janssen-Cilag a strong lead in a limited category
PROSPECTS AND OPPORTUNITIES
Lower growth expected due to competition from e-vapour products and nicotine pouches
Faster-acting products and potential deregulation to maintain positive growth
New price hikes on legal tobacco but ongoing progression of illicit tobacco
CATEGORY INDICATORS
Table 37 Number of Smokers by Gender 2017-2022
CATEGORY DATA
Table 38 Sales of NRT Smoking Cessation Aids by Category: Value 2017-2022
Table 39 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2017-2022
Table 40 NBO Company Shares of NRT Smoking Cessation Aids: % Value 2018-2022
Table 41 LBN Brand Shares of NRT Smoking Cessation Aids: % Value 2019-2022
Table 42 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2022-2027
Table 43 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2022-2027
SLEEP AIDS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
New impetus to sales
Ongoing explosion of innovation and advertising support
Metagenics retains top spot but Lunestil from STADA Arzneimittel AG is a hit
PROSPECTS AND OPPORTUNITIES
Ongoing robust growth expected for sleep aids in the wake of COVID-19 and the context of rising inflation
Possible new competition from Rx products or other consumer health alternatives
Importance of distinctive positioning, and emergence of CBD
CATEGORY DATA
Table 44 Sales of Sleep Aids: Value 2017-2022
Table 45 Sales of Sleep Aids: % Value Growth 2017-2022
Table 46 NBO Company Shares of Sleep Aids: % Value 2018-2022
Table 47 LBN Brand Shares of Sleep Aids: % Value 2019-2022
Table 48 Forecast Sales of Sleep Aids: Value 2022-2027
Table 49 Forecast Sales of Sleep Aids: % Value Growth 2022-2027
EYE CARE IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
No real improvement in eye care in 2022 due to ongoing delays for ophthalmologist appointments
Eye care stays afloat thanks to the ongoing home-working trend and the progression of allergies
GSK’s Terramycin is top brand but Théa Pharma maintains its company lead in a fiercely competitive landscape
PROSPECTS AND OPPORTUNITIES
Despite the ageing of the population, category faces challenge of short lifecycles, cannibalisation and lack of investment
Uncertain progression of self-medication
Ophthalmologists remain essential for the promotion of eye care
CATEGORY DATA
Table 50 Sales of Eye Care by Category: Value 2017-2022
Table 51 Sales of Eye Care by Category: % Value Growth 2017-2022
Table 52 NBO Company Shares of Eye Care: % Value 2018-2022
Table 53 LBN Brand Shares of Eye Care: % Value 2019-2022
Table 54 Forecast Sales of Eye Care by Category: Value 2022-2027
Table 55 Forecast Sales of Eye Care by Category: % Value Growth 2022-2027
WOUND CARE IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
Removal of COVID-19 restrictions and ideal weather lead to peak in wound care sales
However, inflation also plays a part in recovery, while consumers are increasingly price-sensitive
Beiersdorf’s Hansaplast regains its 2019 level but faces growing competition from generics
PROSPECTS AND OPPORTUNITIES
Return to normal, with mature/flat growth expected
Persistently unfavourable conditions for innovation in niche and added-value propositions
Private labels and online players see opportunities ahead
CATEGORY DATA
Table 56 Sales of Wound Care by Category: Value 2017-2022
Table 57 Sales of Wound Care by Category: % Value Growth 2017-2022
Table 58 NBO Company Shares of Wound Care: % Value 2018-2022
Table 59 LBN Brand Shares of Wound Care: % Value 2019-2022
Table 60 Forecast Sales of Wound Care by Category: Value 2022-2027
Table 61 Forecast Sales of Wound Care by Category: % Value Growth 2022-2027
VITAMINS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
Return to normal and modest growth in vitamins
New rebound of sales of vitamin C
Galephar stays ahead and is more dynamic than rivals
PROSPECTS AND OPPORTUNITIES
Much depends on possible resurgence of COVID-19 infection
Less expensive and better targeted single vitamins
Return to maturity and saturation in multivitamins
CATEGORY DATA
Table 62 Sales of Vitamins by Category: Value 2017-2022
Table 63 Sales of Vitamins by Category: % Value Growth 2017-2022
Table 64 Sales of Multivitamins by Positioning: % Value 2017-2022
Table 65 NBO Company Shares of Vitamins: % Value 2018-2022
Table 66 LBN Brand Shares of Vitamins: % Value 2019-2022
Table 67 Forecast Sales of Vitamins by Category: Value 2022-2027
Table 68 Forecast Sales of Vitamins by Category: % Value Growth 2022-2027
DIETARY SUPPLEMENTS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
Sluggish growth expected for dietary supplements in 2022 after a year of normalisation
Dampened interest in immunity but ongoing success of wellbeing and comeback of beauty
Merck Consumer Healthcare/P&G only player with double-digit share in dietary supplements, while smaller players still progress better
PROSPECTS AND OPPORTUNITIES
Possible return of COVID-19 versus soaring inflation
First wellbeing and joint care troubles, then maybe beauty
Uncertain game between mainstream players and medium-sized (and local) operators
CATEGORY DATA
Table 69 Sales of Dietary Supplements by Category: Value 2017-2022
Table 70 Sales of Dietary Supplements by Category: % Value Growth 2017-2022
Table 71 Sales of Dietary Supplements by Positioning: % Value 2017-2022
Table 72 NBO Company Shares of Dietary Supplements: % Value 2018-2022
Table 73 LBN Brand Shares of Dietary Supplements: % Value 2019-2022
Table 74 Forecast Sales of Dietary Supplements by Category: Value 2022-2027
Table 75 Forecast Sales of Dietary Supplements by Category: % Value Growth 2022-2027
WEIGHT MANAGEMENT AND WELLBEING IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
The recovery that was expected in 2021 could finally arrive in 2022
Inflation could dampen the atmosphere, however
Herbalife and Perrigo maintain their leads in their respective channels but yield ground to newcomers
PROSPECTS AND OPPORTUNITIES
2022 could be the swansong of weight management and wellbeing
The issue of cheaper, more natural alternatives and increasingly short lifecycles
Ongoing progression expected for supplement nutrition drinks and perhaps slimming teas
CATEGORY DATA
Table 76 Sales of Weight Management and Wellbeing by Category: Value 2017-2022
Table 77 Sales of Weight Management and Wellbeing by Category: % Value Growth 2017-2022
Table 78 NBO Company Shares of Weight Management and Wellbeing: % Value 2018-2022
Table 79 LBN Brand Shares of Weight Management and Wellbeing: % Value 2019-2022
Table 80 Forecast Sales of Weight Management and Wellbeing by Category: Value 2022-2027
Table 81 Forecast Sales of Weight Management and Wellbeing by Category: % Value Growth 2022-2027
SPORTS NUTRITION IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
Recovery is taking place although many gyms continue to struggle
Explosion of e-commerce and new product development
QNT leads in specialist stores and gyms, and Isostar leads in modern grocery retailers and sport superstores, while House of Nutrition closes in on leading duo
PROSPECTS AND OPPORTUNITIES
Robust growth expected but probably lower than the pre-pandemic CAGR
Dynamic gyms vs home practice
Non-protein/endurance products have room for growth
CATEGORY DATA
Table 82 Sales of Sports Nutrition by Category: Value 2017-2022
Table 83 Sales of Sports Nutrition by Category: % Value Growth 2017-2022
Table 84 NBO Company Shares of Sports Nutrition: % Value 2018-2022
Table 85 LBN Brand Shares of Sports Nutrition: % Value 2019-2022
Table 86 Forecast Sales of Sports Nutrition by Category: Value 2022-2027
Table 87 Forecast Sales of Sports Nutrition by Category: % Value Growth 2022-2027
HERBAL/TRADITIONAL PRODUCTS IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
Lower COVID-19 health concerns and associated stress result in modest growth in herbal/traditional products
Recovery of common seasonal ailments benefits herbal/traditional remedies but to a lesser extent than standard variants
Belgian player, Tilman, benefits from agility and consumer trust
PROSPECTS AND OPPORTUNITIES
Medicinal scandals and the negative impact of inflation
Possible comeback of the old demons of the category: short lifecycle products and unaccountable claims
Herbal sleep aids, dermatologicals, digestive remedies and topical analgesics have notable room for growth
CATEGORY DATA
Table 88 Sales of Herbal/Traditional Products by Category: Value 2017-2022
Table 89 Sales of Herbal/Traditional Products by Category: % Value Growth 2017-2022
Table 90 NBO Company Shares of Herbal/Traditional Products: % Value 2018-2022
Table 91 LBN Brand Shares of Herbal/Traditional Products: % Value 2019-2022
Table 92 Forecast Sales of Herbal/Traditional Products by Category: Value 2022-2027
Table 93 Forecast Sales of Herbal/Traditional Products by Category: % Value Growth 2022-2027
PAEDIATRIC CONSUMER HEALTH IN BELGIUM
KEY DATA FINDINGS
2022 DEVELOPMENTS
More seasonal ailments but ongoing parental reluctance to self-medicate children leads to depressed sales
Sales still driven by paediatric acetaminophen and paediatric cough, cold and allergy remedies
Janssen-Cilag consolidates its leadership ahead of Boots Healthcare
PROSPECTS AND OPPORTUNITIES
An additional threat for paediatric remedies: the risk of shortage
Continuous growth of laxatives and cough, cold and allergy (hay fever) remedies but probable ongoing distrust of paediatric ibuprofen and aspirin
Medical devices and products with a more natural positioning to see further emergence
CATEGORY DATA
Table 94 Sales of Paediatric Consumer Health by Category: Value 2017-2022
Table 95 Sales of Paediatric Consumer Health by Category: % Value Growth 2017-2022
Table 96 Sales of Paediatric Vitamins and Dietary Supplements by Type: % Value 2017-2022
Table 97 NBO Company Shares of Paediatric Consumer Health: % Value 2018-2022
Table 98 LBN Brand Shares of Paediatric Consumer Health: % Value 2019-2022
Table 99 Forecast Sales of Paediatric Consumer Health by Category: Value 2022-2027
Table 100 Forecast Sales of Paediatric Consumer Health by Category: % Value Growth 2022-2027

Report Title: Consumer Health in Belgium


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM